Travera was founded in 2017 to commercialize a breakthrough measurement technology and biomarker developed in the Manalis Laboratory in the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT).
The company’s initial test is based on this technology; a new measurement tool called the Suspended Microchannel Resonator (SMR) that makes exquisitely precise measurements of the effects of cancer drugs on cancer cells.